Jonathan Goodman

MPhil, Oncology Editor

Most Recent Articles by Jonathan Goodman

Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine

Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine

By

Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.

Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer

Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer

By

Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.

Non-small Cell Lung Cancer Metastasis at Diagnosis May Be Predicted by Genetic Mutations

Non-small Cell Lung Cancer Metastasis at Diagnosis May Be Predicted by Genetic Mutations

By

ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.

Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC

Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC

By

Valuable information regarding patients' life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.

Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy

Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy

By

The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.

More Articles by Jonathan Goodman

Sign Up for Free e-newsletters